The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously 14-0 that the safety and immunogenicity data of UK pharma giant GlaxoSmithKline (LSE: GSK) H5N1 adjuvanted influenza vaccine candidate supports its licensure for the active immunization for the prevention of disease in people aged 18 years and older who are at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.
“GSK has been collaborating with the US Department of Health and Human Services since 2006 to develop this H5N1 vaccine and we are pleased with the positive vote recommending its approval,” commented Bruce Innis, vice president, GSK Global Vaccines Discovery and Development. “We now look forward to a final decision by the FDA later this year and to also continuing our collaboration with the US government on public health issues,” he added.
The VRBPAC provides the FDA with independent expert advice and non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA. According to agency regulations, the FDA is scheduled to conclude its review for the vaccine in December 2012. If approved, the vaccine is to be used only according to official guidance from the US government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze